Eiger BioPharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Apelian
- Full Time Employees
- 56
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2155 Park Boulevard Palo Alto CA United States of America 94306
- IPO Date
- Jan 30, 2014
- CIK
- 0001305253
- Website
- eigerbio.com
- Similar Companies
- Business
- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) develops and commercializes therapies for rare diseases with high unmet medical needs, including hepatitis delta virus, progeroid laminopathies and metabolic disorders such as post-bariatric hypoglycemia and congenital hyperinsulinism; its approved product Zokinvy (lonafarnib) treats progeria and progeroid laminopathies; the company previously advanced lonafarnib, boosted with ritonavir, and peginterferon lambda for hepatitis delta virus, as well as avexitide, a GLP-1 receptor antagonist, for hyperinsulinemic hypoglycemia indications. Founded in 2008 and headquartered in Palo Alto, California, Eiger BioPharmaceuticals operates primarily in the United States with a focus on North America and Europe for its commercial and clinical activities. In recent developments, the company filed for Chapter 11 bankruptcy in April 2024 and completed a liquidation by September 2024; it sold Zokinvy to Sentynl Therapeutics, avexitide to Amylyx Pharmaceuticals for $35.1 million in July 2024 and lonafarnib with peginterferon lambda programs to Eiger InnoTherapeutics in September 2024 as part of its asset management and restructuring under bankruptcy protection.
Healthcare stocks fade as obesity-drug optimism fades
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals: Wall Street Has High Expectations For Faltering Battleground Stock
EIGR Stock: 23.53% Surge Explanation
7 Cheap But Risky Biotech Stocks
Best Penny Stocks To Buy? 4 To Watch Before 2023
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
Eiger BioPharmaceuticals: A Compelling High Beta Story
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call Transcript
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
Eiger's stock falls 20% after telling investors it won't seek FDA authorization for COVID-19 drug
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates